or Try an Advanced Search...

    ETF Components for FMED - Fidelity Disruptive Medicine ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    BSX A -0.37 5.74
    UNH C 0.54 3.93
    CNC C -0.07 3.52
    DHR C -0.12 3.47
    MASI D -11.41 3.47
    ISRG C -2.02 3.36
    RPRX D -1.11 2.82
    SYK D -1.30 2.57
    PEN F -3.44 2.55
    LEGN F -2.26 2.41

    Represented by ETF Holdings

    Keywords: S&P 500 Medicine Medical Equipment Medical Technology Catheter Claims Processing Disease Endoscopy Formulary Health Care Health Management Interventional Radiology Managed Care Medicaid Surgical Equipment Surgical Tools 3 D Ablation Advisory Consulting Services Analytical Instruments
    Industries: Medical Devices Biotechnology Health Care Plans Medical Instruments & Supplies Diagnostics & Research

    Recent News for Fidelity Disruptive Medicine ETF & its Holdings

    Date Stock Title
    May 8 RPRX Teva, Medincell succeed in late-stage trial for injectable schizophrenia therapy
    May 8 MASI Masimo Corp (MASI) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...
    May 8 PEN Penumbra, Inc. (PEN) Q1 2024 Earnings Call Transcript
    May 8 MASI Masimo Corporation (MASI) Q1 2024 Earnings Call Transcript
    May 7 MASI Masimo (MASI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
    May 7 MASI Masimo Corp (MASI) Q1 2024 Earnings: Surpasses Revenue Estimates, Aligns with EPS Projections
    May 7 PEN Penumbra Inc (PEN) Surpasses Analyst Revenue Forecasts in Q1 2024
    May 7 DHR Danaher declares $0.27 dividend
    May 7 DHR Danaher to Present at Bank of America Securities Healthcare Conference
    May 7 MASI Masimo Non-GAAP EPS of $0.77 beats by $0.07, revenue of $492.8M beats by $5.08M
    May 7 PEN Penumbra Non-GAAP EPS of $0.41 beats by $0.03, revenue of $278.7M beats by $4.2M
    May 7 PEN Penumbra, Inc. Reports First Quarter 2024 Financial Results
    May 7 MASI Masimo Reports First Quarter 2024 Financial Results
    May 7 CNC Select Medical's (SEM) Shares Up 12.9% Since Q1 Earnings Beat
    May 7 UNH 'Telehealth 1.0 is dead,' but don't count out digital health just yet
    May 7 BSX Integra's (IART) Q1 Earnings Match Estimates, Margins Down
    May 7 UNH 13 Best Stocks That Will Always Grow
    May 7 ISRG 13 Best Stocks That Will Always Grow
    May 7 BSX Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
    May 7 UNH 12 Best Investments for Beginners in 2024
    The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
    Back to the Main FMED Page...